Αλογλιπτίνη (Greek Wikipedia)

Analysis of information sources in references of the Wikipedia article "Αλογλιπτίνη" in Greek language version.

refsWebsite
Global rank Greek rank
4th place
4th place
2nd place
3rd place
1st place
1st place
447th place
368th place
68th place
24th place
low place
low place
3,547th place
low place
3,558th place
7,054th place
low place
low place
low place
low place
low place
low place

aace.com

doi.org

doi.org

  • Feng, Jun; Zhang, Zhiyuan; Wallace, Michael B.; Stafford, Jeffrey A.; Kaldor, Stephen W.; Kassell, Daniel B.; Navre, Marc; Shi, Lihong; Skene, Robert J.; Asakawa, Tomoko; Takeuchi, Koji; Xu, Rongda; Webb, David R.; Gwaltney II, Stephen L. (2007). "Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV". J. Med. Chem. 50 (10): 2297–2300. doi:10.1021/jm070104l. PMID 17441705.
  • Seino, Yutaka; Fujita, Tetsuya; Hiroi, Shinzo; Hirayama, Masashi; Kaku, Kohei (September 2011), "Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study (abstract only)", Current Medical Research and Opinion, 27 (9): 1781–1792, doi:10.1185/03007995.2011.599371, PMID 21806314
  • Bosi, Emanuele; Ellis, G.C.; Wilson, C.A.; Fleck, P.R. (October 2011), "Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study", Diabetes, Obesity and Metabolism (published October 27, 2011), 13 (12): 1088–1096, doi:10.1111/j.1463-1326.2011.01463.x, PMID 21733058

dx.doi.org

europa.eu

ema.europa.eu

fda.gov

genengnews.com

nih.gov

ncbi.nlm.nih.gov

  • Feng, Jun; Zhang, Zhiyuan; Wallace, Michael B.; Stafford, Jeffrey A.; Kaldor, Stephen W.; Kassell, Daniel B.; Navre, Marc; Shi, Lihong; Skene, Robert J.; Asakawa, Tomoko; Takeuchi, Koji; Xu, Rongda; Webb, David R.; Gwaltney II, Stephen L. (2007). "Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV". J. Med. Chem. 50 (10): 2297–2300. doi:10.1021/jm070104l. PMID 17441705.
  • Saisho, Y (2015). «Alogliptin benzoate for management of type 2 diabetes.». Vascular Health and Risk Management 11: 229–43. doi:10.2147/VHRM.S68564. PMID 25914541. 
  • Seino, Yutaka; Fujita, Tetsuya; Hiroi, Shinzo; Hirayama, Masashi; Kaku, Kohei (September 2011), "Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study (abstract only)", Current Medical Research and Opinion, 27 (9): 1781–1792, doi:10.1185/03007995.2011.599371, PMID 21806314
  • Bosi, Emanuele; Ellis, G.C.; Wilson, C.A.; Fleck, P.R. (October 2011), "Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study", Diabetes, Obesity and Metabolism (published October 27, 2011), 13 (12): 1088–1096, doi:10.1111/j.1463-1326.2011.01463.x, PMID 21733058
  • «Alogliptin after acute coronary syndrome in patients with type 2 diabetes». N. Engl. J. Med. 369 (14): 1327–35. October 2013. doi:10.1056/NEJMoa1305889. PMID 23992602. http://espace.library.uq.edu.au/view/UQ:382398/UQ382398_OA.pdf. 
  • «Saxagliptin, alogliptin, and cardiovascular outcomes». N. Engl. J. Med. 370 (5): 483–484. January 2014. doi:10.1056/NEJMc1313880. PMID 24482824. 

pubmedcentral.nih.gov

pharmatimes.com

takeda.com

uq.edu.au

espace.library.uq.edu.au

utsandiego.com

web.archive.org